Acta Chim. Slov. 2008, 55, 53–57
53
Mini review
Multiple Signaling Pathways Coordinate CYP17 Gene Expression in the Human Adrenal Cortex
Marion B. Sewer*, Donghui Li, Eric B. Dammer, Srinath Jagarlapudi and Natasha Lucki
School of Biology and Parker H. Petit Institute for Bioengineering & Biosciences, Georgia Institute of Technology, Atlanta, GA 30332-0230
* Corresponding author: marion.sewer@biology.gatech.edu
Received: 17-09-2007
Abstract
Optimal levels of steroid hormone biosynthesis are assured by the integration of several regulatory mechanisms, including substrate delivery, enzymatic activity, and gene transcription. In the human adrenal cortex, optimal glucocorticoid secretion is achieved by the actions of adrenocorticotropin (ACTH), which exerts transcriptional pressure on all genes involved in steroidogenesis. One of these genes is CYP17, which encodes P450 17?-hydroxylase-17,20 lyase, a key enzyme in the production of cortisol and adrenal androgens. Levels of CYP17 transcription are regulated by multiple regulatory mechanisms that act to respond to various signaling cues. These cues are coordinated in a developmental, species-, and tissue-specific manner, with an additional time/circadian-dependent level of regulation. This brief review will highlight some of the signal transduction cascades and transcription factors that have been shown to modulate CYP17 gene expression in the adrenal cortex.
Keywords: CYP17, adrenocorticotropin, angiotensin II, cAMP, steroid hydroxylase, steroidogenic factor-1, PKA
1. Overview
Steroid hormones exert control of diverse physiological processes by serving as ligands for intracellular and plasma membrane receptors. While ligand binding to plasma membrane receptors is coupled to the rapid activation of signaling pathways, hormone-bound intracellular receptors are transcription factors, and thus alter gene expression by binding to DNA response elements. Cortisol, aldosterone, and adrenal androgens are the primary bioac-tive steroid hormones that are produced in the human adrenal cortex. Like all classes of steroid hormones, biosynthesis occurs in a multi-step process and requires the actions of both members of the cytochrome P450 monooxy-genase superfamily, as well as hydroxysteroid dehydroge-nases. These enzymes catalyze the conversion of cholesterol to aldosterone, cortisol, or adrenal androgens in a zone-specific manner. Aldosterone, a mineralocorticoid, is a key regulator of sodium and potassium homeostasis and is produced in the zona glomerulosa, whereas adrenal androgens are synthesized in the zona reticularis. The glu-cocorticoid cortisol directs carbohydrate metabolism, as well as modulates blood pressure and the immune re-
sponse, and is produced in the zona fasciculata. This review will focus on the transcriptional regulation of CYP17. CYP17 is localized in the endoplasmic reticulum and catalyzes both the 17-hydroxylation of pregnenolone and progesterone and the 17,20 bond scission of 17-hydroxypregnenolone and 17-hydroxyprogesterone. Because the hydroxylase activity is required for glucocorti-coid production and both the hydroxylase and lyase activities are essential for adrenal androgen biosynthesis, the activities of this enzyme are positioned to direct hormone identity and adrenal output.
2. Signaling Pathways
Steroidogenic capacity is governed by peptide hormones that are secreted by the anterior pituitary in response to signaling from the hypothalamus. These peptide molecules evoke changes in steroid hormone output by acting as ligands for G protein-coupled receptors. Although numerous signaling molecules have been implicated as regulators of steroidogenic gene transcription in the adrenal cortex,1 the most important factor in glucocorti-
Sewer et al.:  Multiple Signaling Pathways Coordinate CYP17 Gene Expression ...
Acta Chim. Slov. 54
coid production and CYP17 regulation is ACTH.2–7 This peptide hormone promotes steroidogenesis by activating intracellular signaling pathways that facilitate cholesterol uptake, transport, and delivery,8,9 and induce steroidogenic gene transcription.2,10–14 The trophic actions of ACTH are multi-faceted and allow for rapid production of steroid hormones by increasing substrate availability and sustained biosynthetic capacity by inducing gene expression.
Perhaps the most widely studied pathway is the cAMP signaling cascade. ACTH binding to the melanocortin 2 receptor results in the activation of the adenylyl cyclase, increased intracellular cAMP and activation of the cAMP-dependent protein kinase (PKA). PKA then acts to phos-phorylate downstream targets, such as CREM (cAMP response element modulator), which induces steroidogenic acute regulatory protein (StAR) transcription,15 and hormone sensitive lipase,16 for the production of free cholesterol. It is anticipated that future research will identify other proteins whose function in steroidogenesis is regulated by PKA-catalyzed phosphorylation.
We have shown that ACTH rapidly activates the synthesis and secretion of the bioactive sphingolipid sphingosine-1-phosphate (S1P).17,18 S1P is then secreted into the extracellular space where it binds to members of the S1P family of GPCRs, ultimately resulting in CYP17 transcription and cortisol production.17,18 Since we have recently identified another sphingolipid, sphingosine, as an endogenous antagonist of the nuclear receptor steroidogenic factor-1 (SF-1, NR5A1, Ad4BP),19 it is probable that ACTH also increases the transactivation potential of SF-1 by promoting dissociation of sphingosine and rapid conversion to S1P. ACTH also rapidly and transiently activates salt-inducible kinase 1, which results in translocation of the enzyme from the nucleus to the cytoplasm where it represses the transcription of steroidogenic enzymes,20–23 thereby providing a mechanism by which adrenocortical cells fine-tune the kinetics of hormone output.
Activation of growth factor signaling pathways such as the mitogen-activated kinase (MAPK) cascade modulates CYP17 gene expression.24–28 Both epidermal growth factor and basic fibroblast growth factor, probably by activating the MAPK pathway, suppress CYP17 mRNA expression in H295R cells.26 Src kinase, another effector in growth factor signaling, modulates CYP17 mRNA expression and controls adrenal androgen biosynthesis in H295R cells.29 The phorbol ester TPA (12-O-tetrade-canoyl-phorbol-13 acetate), which activates protein ki-nase C, represses CYP17 mRNA expression in mouse ad-renal.28 Interestingly, recent studies have found that the thiazolidinedione and peroxisome proliferator activated receptor-? (PPAR?) agonist pioglitazone suppresses the expression of CYP17 via a PPAR?-independent and MAPK-dependent mechanism in the H295R cell line.30
Another recently identified signaling mediator of al-dosterone and cortisol production is the Wnt-signaling pathway.31 Activation of the Wnt signaling pathway and
Sewer et al.:  Multiple Signaling Pathways
2008, 55, 53-57
transfection of a constitutively active ί-catenin mutant in H295R cells both induced StAR reporter gene activity, adding to a rapidly expanding list of signaling molecules that modulate adrenocortical steroidogenesis.31 Given that SF-1 synergizes with ί-catenin in the activation of the rat inhibin alpha gene during adrenal development,32 it is likely that Wnt-dependent signaling cascades will be found to play other critical roles in steroidogenesis, not only in the adrenal gland, but in other steroidogenic tissues as well. Additionally, the cloning and functional characterization of T-cell factor 4N has revealed that this transcription factor synergizes with ί-catenin and SF-1 in transactivating target genes,33 identifying another mechanism by which protein-protein interactions may modulate steroidogenic gene transcription.
Another emerging mechanism by which an extracellular signaling factor modulates CYP17 gene expression is in the production of cortisol and dihydroepiandrosterone in the fetal adrenal, where placental corticotropin-releas-ing hormone (CRH) signaling induces the mRNA expression of several steroidogenic genes, including CYP17, and directly stimulates hormone secretion.34,35 Interestingly, the stimulatory effects of CRH on cortisol production in human fetal adrenal cells were found to be additive with
ACTH.34
3. Transcription Factors
Seminal work by the Miller and Waterman laboratories on the human and bovine CYP17 promoters, established the role of trophic hormone-activated transcription in mediating increased steroid hormone output. The stimulatory actions of ACTH and cAMP on steroidogenic gene transcription were initially demonstrated using primary cultures of bovine adrenal cells.36 Although an increase in mRNA expression supported a role for transcriptional activation in maintaining steroidogenic capacity, studies using nuclear-run on assays confirmed that gene transcription is a prerequisite for cortisol secretion.37 Because binding of ACTH to the melanocortin 2 receptor activates adenylyl cyclase and increases intracellular cAMP, it was originally hypothesized that the cAMP response element binding protein (CREB) transcription factor mediated the induction of steroidogenic gene expression. However, unlike the rapid induction of transcription observed for other CREB targets such as the immediate early genes c-Fos and Jun-B,38,39 the stimulatory actions of cAMP on steroidogenic gene expression was delayed and took hours when compared to cAMP-evoked changes in the expression of immediate early genes.37,40 Moreover, in contrast to other CREB targets, increased steroid hydroxylase gene expression was cycloheximide-sensitive,41 indicating the requirement for the translation of a protein(s) required for conferring ACTH/cAMP-dependent gene transcription. Indeed, subsequent studies by several groups led to
Coordinate CYP17 Gene Expression ...
Acta Chim. Slov. 2008, 55, 53–57
the identification of unique cAMP responsive sequences in the promoters of steroidogenic genes that were essential for expression in response to ACTH signaling.
For the human CYP17 gene, cAMP-dependent transcription requires a region within the first approximately 65 base pairs upstream of the transcriptional initiation site.42,43 ACTH/cAMP promote the assembly of a ternary complex containing SF-1, p54,nrb and polypyrimidine tract-binding-protein-associated splicing factor PSF.43 Significantly, the affinity of this trimer for the human CYP17 promoter is positively regulated by cAMP43 and is sensitive to kinase and phosphatase activity.44 SF-1 is a nuclear receptor that is essential for steroid hormone biosynthesis, endocrine development and function, and sex differentiation.45–52 The ability of SF-1 to modulate gene expression and steroidogenesis is regulated by phosphory-lation,44,53–55 sumoylation,56,57 acetylation,58–60 and protein-protein interactions.43,61–67 In addition to the roles of post-translational modification and protein-protein interaction, a role for ligand binding has emerged as integral in controlling receptor function.19,68–72
Recently, we have demonstrated that sphingosine (SPH)19,73 and phosphatidic acid (PA)70 are endogenous ligands for SF-1. Using mass spectrometry to analyze SF-1 that was isolated from the H295R human adrenocortical cell line, we identified SPH as an endogenous antago-nist19. SPH is bound to SF-1 in unstimulated H295R cells and dissociates from the receptor in response to ACTH/cAMP stimulation. We determined that SPH inhibited the ability of SF-1 to activate CYP17 gene transcription by promoting the binding of corepressor complexes to the receptor. Intriguingly, in vitro assays demonstrated that SF-1 can bind to several sphingolipids and phospho-lipids19, indicating that the receptor has multiple ligands that are predicted to act in a cell-, tissue-, or developmental stage-specific manner to control target gene expression. To identify agonists for SF-1, we once again performed mass spectrometric analysis of the purified receptor and identified PA as the predominant phospholipid that bound to SF-1 in the human adrenal cortex. Unlike SPH, PA preferentially bound to the receptor in response to ACTH/cAMP stimulation and was an agonist. PA activated the transcription of CYP17 and several other steroido-genic genes. Stimulation of the ACTH/cAMP signaling pathway increased nuclear PA concentrations by activating diacylglycerol kinase theta (DGK?).70 Interestingly, DGK? binds to SF-1, indicating that ligand binding is facilitated by a direct interaction between the nuclear receptor and DGK?. Based on these findings, we propose a mechanism by which SPH maintains low levels of steroid hormone production in the absence of ACTH/cAMP stimulation, and perhaps in response to growth factor stimulation, by keeping SF-1 in an inactive conformation, thereby stabilizing interactions between the receptor and corepres-sor proteins.61 Upon ACTH/cAMP stimulation, SPH dissociates from the receptor and PA binds to the ligand
binding pocket, thus promoting the interaction with coac-tivator proteins such as steroid receptor coactivator-1 and the histone acetyltransferase GCN5 (general control non-derepressed 5), which we have shown to bind to the CYP17 promoter in a complex with SF-1 in response to ACTH/cAMP signaling.61
In addition to the interaction of SF-1-containing complexes with the proximal promoter, the stimulatory protein (Sp) family of transcription factors also plays an integral role in modulating basal CYP17 gene expression.74,75 A complex containing Sp1, Sp3, and nuclear factor-1C bind to a second element distal to the SF-1 binding site.74 Another transcription factor that regulates the expression of the human CYP17 gene is sterol regulatory element binding protein 1c (SREBP1c).17 SREBPs are transcription factors that not only function as cholesterol sensors,76 but also regulate steroidogenic genes including StAR77 and CYP17.17 In response to the sphingolipid S1P, SREBP1c is cleaved and transported to the nucleus where it activates
CYP17 transcription.17
Another family of transcription factors that are key in maintaining steroidogenic gene expression in the human adrenal cortex is the GATA family of transcription factors. GATA transcription factors control gene expression, cell differentiation, and tumorigenesis in diverse cell types, including steroidogenic factories such as the gonads and adrenal gland.78–82 A role for GATA-6 in regulating the transcription of CYP17 in the H295R human adrenocortical cell line has been established, where synergy between GATA-6 and SF-1 directs adrenal androgen biosynthe-sis.83 Interestingly, the expression of GATA-6 is positively regulated by cAMP,84 suggesting a role for trophic hormone stimulation in fine-tuning the function of this transcription factor in steroidogenic tissues. The direct interaction of GATA-6 or GATA-4 and Sp1 mediates constitutive expression of CYP17.75
4. Summary
The studies discussed in this review highlight some of the research that has led to our current understanding of the mechanism underlying CYP17 gene expression in the human adrenal cortex. It is expected that further studies will reveal more about the complex signaling pathways and transcriptional regulatory networks that maintain CYP17 transcription and optimal cortisol output.
5. Abbreviations
ACTH, adrenocorticotropin; PKA, cAMP-dependent protein kinase; StAR, steroidogenic acute regulatory protein; MAPK, mitogen activated protein kinase; PPAR?, peroxisome proliferator-activated receptor ?; CREM, cAMP response element modulator; SF-1, steroidogenic
Sewer et al.:  Multiple Signaling Pathways Coordinate CYP17 Gene Expression ...
Acta Chim. Slov. 56
factor-1; CREB, cAMP response element binding protein; PA, phosphatidic acid; SPH, sphingosine; DGK?, diacyl-glycerol kinase ?; CRH, corticotropin releasing hormone; SREBP1c, sterol regulatory element binding protein 1c
6. References
1. M. Ehrhart-Bornstein, J. P. Hinson, S.R. Bornstein, W. A. Scherbaum, and G. P. Vinson. Endocrine Reviews 1998 19, 101–143.
2. M. B. Sewer, and M. R. Waterman. Microsc Res Tech 2003 61, 300–307.
3. J. J. Enyeart. Vitam Horm 2005 70, 265–279.
4. A. Spat, and L. Hunyady. Physiol. Rev. 2004 84, 489–539.
5. R. H. Foster. J Mol Endocrinol. 2004 32, 893–902.
6. N. Gallo-Payet, and M. D. Payet. Microsc Res Tech 2003 61, 275–287.
7. M. B. Sewer, E. B. Dammer, and S. Jagarlapudi. Drug Metab Rev 2007 39, 371–388.
8. W. L. Miller. Mol Endocrinol 2007 21, 589–601.
9. D. Stocco, X. Wang, Y. Jo, and P. R. Manna. Mol Endocrinol
2005 19, 2647–2659.
10. C. C. D. Moore, and W. L. Miller. J Steroid Biochem Mol Biol 1991 40, 517–525.
11. W. L. Miller. Endocrine Reviews 1988 9, 295–318.
12. M. R. Waterman, and D. S. Keeney. (1996) Diverse molecular mechanisms regulate the expression of steroid hydroxy-lase genes required for production of ligands for nuclear receptors. In: Jefcoate CR (ed). Physiological Functions of Cytochrome P450 in Relation to Structure and Regulation, JAI Press, Inc., Greenwich, CT
13. M. B. Sewer, and M. R. Waterman. Rev. in Endocrine and Metabolic Disorders 2001 2, 269–274.
14. M. B. Sewer, and M. R. Waterman. Endocr Res 2002 28, 551–558.
15. T. Sugawara, N. Sakuragi, and H. Minakami. J Endocrinol.
2006 191, 327–337.
16. C. R. Jefcoate, B. C. McNamara, I. Artemenko, and T. Yamazaki. J. Steroid Biochem. Mol. Biol. 1992 43, 751–767.
17. T. Ozbay, A. Rowan, A. Leon, P. Patel, and M. B. Sewer. Endocrinology 2006 147, 1427–1437.
18. T. Ozbay, A. H. Merrill Jr., and M. B. Sewer. Endocr Res 2004 30, 787–794.
19. A. N. Urs, E. Dammer, and M. B. Sewer. Endocrinology 2006 147, 5249–5258.
20. H. Takemori, J. Doi, N. Horike, Y. Katoh, L. Min, X. Z. Lin, Z. N. Wang, M. Muraoka, and M. Okamoto. J Steroid Biochem Mol Biol 2003 85, 397–400.
21. Y. Katoh, H. Takemori, L. Min, M. Muraoka, J. Doi, N. Horike, and M. Okamoto. Eur J Biochem 2004 271, 4307–4319.
22. Y. Katoh, H. Takemori, N. Horike, J. Doi, M. Muraoka, L. Min, and M. Okamoto. Mol Cell Endocrinol. 2004 217, 109–112.
23. J. Doi, H. Takemori, X. Z. Lin, N. Horike, Y. Katoh, and M. Okamoto. J Biol Chem 2002 277, 15629–15637.
2008, 55, 53-57
24. V.L. Nelson-Degrave, J. K. Wickenheisser, K. L. Hendricks, T. Asano, M. Fujishiro, R. S. Legro, S. R. Kimball, J. F. Strauss 3rd, and J. M. McAllister. Mol Endocrinol 2005 19, 379–390.
25. Z. Li Z, and A. L. Johnson. Biol Reprod 1993 49, 1293–1302.
26. J. Doi, H. Takemori, M. Ohta, Y. Nonaka, and M. Okamoto. J. Endocrinol. 2001 168, 87–94.
27. C. H. Wu, Y. F. Chen, J. Y. Wang, M. C. Hsieh, C. S. Yeh, S. T. Lian, S. J. Shin, and S. R. Lin. Br J Cancer 2002 87, 1000–1005.
28. S. T. Brentano, J. Picado-Leonard, S. H. Mellon, C. C. Moore, and W. L. Miller. Mol Endocrinol 1990 4, 1972–1979.
29. R. Sirianni, B. R. Carr, S. Ando, and W. E. Rainey. J Mol Endocrinol. 2003 30, 287–299.
30. P. Kempna, G. Hofer, P. E. Mullis, and C. E. Fluck. Mol Pharmacol 2007 71, 787–798.
31. S. Schinner, H. S. Willenberg, D. Krause, M. Schott, V. Lamounier-Zepter, A. W. Krug, M. Ehrhart-Bornstein, S. R. Bornstein, and W. A. Scherbaum. Int J Obes (Lond) 2007 31, 864–870.
32. B. M. Gummow, J. N. Winnay, and G. D. Hammer. J Biol Chem 2003 278, 26572–26579.
33. J. A. Kennell, E. E. O’Leary, B. M. Gummow, G. D. Hammer, and O. A. MacDougald. Mol Cell Biol 2003 23, 5366–5375.
34. R. Sirianni, K. S. Rehman, B. R. Carr, C. R. Parker Jr, and W. E. Rainey. J Clin Endocrinol Metab 2005 90, 279–285.
35. R. Sirianni, B. A. Mayhew, B. R. Carr, C. R. Parker Jr, and W. E. Rainey. J Clin Endocrinol Metab 2005 90, 5393– 5400.
36. M. X. Zuber, M. E. John, T. Okamura, E. R. Simpson, and M. R. Waterman. J. Biol. Chem. 1986 261, 2475–2485.
37. M. E. John, M. C. John, V. Boggaram, E. R. Simpson, and M. R. Waterman. Proc Natl Acad Sci U S A 1986 83, 4715–4719.
38. I. Viard, S. H. Hall, C. Jaillard, M. C. Berthelon, and J. M. Saez. Endocrinology 1992 130, 1193–1200.
39. W. J. Roesler, G. R. Vandenbar, and R. W. Hanson. J. Biol. Chem. 1988 263, 9063–9066.
40. M. R. Waterman, and E. R. Simpson. Recent Prog Horm Res 1989 45, 533–563.
41. M. R. Waterman. J. Biol. Chem. 1994 269, 27783–27786.
42. H. Rodriguez, D. W. Hum, B. Staels, and W. L. Miller. J. Clin. Endocrinol Metab 1997 82, 365–371.
43. M. B. Sewer, V. Nguyen, C. J. Huang, P. W. Tucker, N. Kagawa, and M. R. Waterman. Endocrinology 2002 143, 1280–1290.
44. M. B. Sewer, and M. R. Waterman. Endocrinology 2002 143, 1769–1777.
45. D. S. Lala, D. A. Rice, and K. L. Parker. Mol Endocrinol 1992 6, 1249–1258.
46. X. Luo, Y. Ikeda, and K. L. Parker. Cell 1994 77, 481–490.
47. Y. Ikeda, X. Luo, R. Abbud, J. H. Nilson, and K. L. Parker. Mol Endocrinol 1995 9, 478–486.
Sewer et al.:  Multiple Signaling Pathways Coordinate CYP17 Gene Expression ...
Acta Chim. Slov. 2008, 55, 53–57
57
48. H. A. Ingraham, D. S. Lala, Y. Ikeda, X. Luo, W. Shen, M. W. Nachtigal, R. Abbud, J. H. Nilson, and K. L. Parker. Genes Dev. 1994 8, 2302–2312.
49. K. L. Parker, D. A. Rice, D. S. Lala, Y. Ikeda, X. Luo, M. Wong, M. Bakke, L. Zhao, C. Frigeri, N. A. Hanley, N. Stallings, and B. P. Schimmer. Recent Prog Horm Res 2002 57, 19–36.
50. K. M. McClellan, K. L. Parker, and S. Tobet. Front Neuroen-docrinol 2006 27, 193–209.
51. M. Bakke, L. Zhao, N. A. Hanley, and K. L. Parker. Mol Cell Endocrinol 2001 171, 5–7.
52. L. Zhao, M. Bakke, N. A. Hanley, G. Majdic, N. R. Stallings, P. Jeyasuria, and K. L. Parker. Mol Cell Endocrinol. 2004 215, 89–94.
53. G. D. Hammer, I. Krylova, Y. Zhang, B. D. Darimont, K. Simpson, N. L. Weigel, and H. A. Ingraham. Mol Cell 1999 3, 521–526.
54. M. Desclozeaux, I. N. Krylova, F. Horn, R. J. Fletterick, and H. A. Ingraham. Mol Cell Biol 2002 22, 7193–7203.
55. M. B. Sewer, and M. R. Waterman. J Mol Endocrinol 2002 29, 163–174.
56. T. Komatsu, H. Mizusaki, T. Mukai, H. Ogawa, D. Baba, M. Shirakawa, S. Hatakeyama, K. I. Nakayama, H. Yamamoto, A. Kikuchi, and K. Morohashi. Mol Endocrinol 2004 18, 2451–2462.
57. W. Y. Chen, W. C. Lee, N. S. Hsu, F. Huang, and B. C. Chung. J Biol Chem 2004 279, 38730–38735.
58. A. L. Jacob, J. Lund, P. Martinez, and L. Hedin. J Biol Chem 2001 276, 37659–37664.
59. W. Y. Chen, L. J. Juan, and B. C. Chung. Mol Cell Biol 2005 25, 10442–10453.
60. S. L. Ishihara, and K. Morohashi. Biochem Biophys Res Commun 2005 329, 554–562.
61. E. B. Dammer, A. Leon, and M. B. Sewer. Mol Endocrinol 2007 21, 415–438.
62. D. Monte, F. DeWitte, and D. W. Hum. J. Biol. Chem. 1998 273, 4585–4591.
63. D. Zhou, K. M. Quach, C. Yang, S. Y. Lee, B. Pohajdak, and S. Chen. Mol Endocrinol 2000 14, 986–998.
64. B. Borud, T. Hoang, M. Bakke, A. L. Jacob, J. Lund, and G. Mellgren. Mol Endocrinol 2002 16, 757–773.
65. L. A. Li, D. S. Lala, and B. Chung. Biochem Biophys Res Commun 1998 250, 318–320.
66. L. A. Li, E. F. L. Chiang, J. C. Chen, N. C. Hsu, Y. J. Chen, and B. Chung. Mol Endocrinol 1999 13, 1588–1598.
67. J. N. Winnay, and G. D. Hammer. Mol Endocrinol 2006 20W. Wang, C. Zhang, A. Marimuthu, H. I. Krupka, M. Tabrizizad, R. Shelloe, U. Mehra, K. Eng, H. Nguyen, C. Settachatgul, B. Pow
Povzetek
Zdru`evanje ve~ih mehanizmov uravnavanja, kot so dostopnost substrata, encimska aktivnost in prepisovanje genov, zagotavlja optimalno koli~ino steroidnih hormonov. V skorji nadledvi~ne `leze pri ~loveku je optimalno izlo~anje gluko-kortikoidov zagotovljeno z delovanjem adrenokortikotropina (ACTH), ki izvaja transkripcijski pritisk na vse gene, vpletene v steroidogenezo. Eden od teh genov je CYP17, ki kodira P450c17?, klju~ni encim v proizvodnji kortizola in an-drogenov nadledvi~ne `leze. Raven prepisovanja CYP17 je uravnavana z mnogimi regulatornimi mehanizmi, ki se odzivajo na razli~ne signale. Signalne poti so koordinirane na razvojni, vrstno- in tkivno-specifi~ni ravni, z dodatno ~asov-no/cirkadi~no ravnijo uravnavanja. Ta kratek pregled bo izpostavil klju~ne kaskade prenosa signala in opisal transkrip-cijske faktorje, za katere je znano, da vplivajo na izra`anje gena CYP17 v skorji nadledvi~ne `leze.
Sewer et al.:  Multiple Signaling Pathways Coordinate CYP17 Gene Expression ...